Your browser is no longer supported. Please, upgrade your browser.
Settings
NKTR [NASD]
Nektar Therapeutics
Index- P/E- EPS (ttm)-2.49 Insider Own1.00% Shs Outstand179.72M Perf Week1.99%
Market Cap3.57B Forward P/E- EPS next Y-2.44 Insider Trans-30.93% Shs Float177.86M Perf Month-17.68%
Income-444.40M PEG- EPS next Q-0.71 Inst Own95.60% Short Float10.84% Perf Quarter6.74%
Sales152.90M P/S23.38 EPS this Y1.20% Inst Trans-0.66% Short Ratio15.33 Perf Half Y8.32%
Book/sh5.99 P/B3.17 EPS next Y18.10% ROA-27.20% Target Price31.64 Perf Year3.43%
Cash/sh5.64 P/C3.37 EPS next 5Y-7.30% ROE-37.00% 52W Range15.40 - 26.75 Perf YTD11.76%
Dividend- P/FCF- EPS past 5Y-32.40% ROI-39.50% 52W High-28.97% Beta1.52
Dividend %- Quick Ratio9.70 Sales past 5Y-7.90% Gross Margin87.30% 52W Low23.42% ATR0.98
Employees718 Current Ratio9.80 Sales Q/Q-30.70% Oper. Margin- RSI (14)40.09 Volatility4.36% 4.98%
OptionableYes Debt/Eq0.00 EPS Q/Q-1.30% Profit Margin- Rel Volume1.34 Prev Close19.36
ShortableYes LT Debt/Eq0.00 EarningsFeb 25 AMC Payout- Avg Volume1.26M Price19.00
Recom2.40 SMA20-5.01% SMA50-11.83% SMA200-3.25% Volume1,680,473 Change-1.86%
Feb-22-21Downgrade The Benchmark Company Buy → Hold
Jan-06-21Initiated Stifel Hold $18
Sep-14-20Initiated JP Morgan Neutral $26
Jun-10-20Downgrade CFRA Hold → Sell
May-12-20Reiterated H.C. Wainwright Neutral $32 → $26
Apr-22-20Initiated The Benchmark Company Buy $26
Mar-30-20Upgrade Goldman Sell → Neutral $18 → $20
Mar-04-20Initiated Barclays Overweight $30
Feb-03-20Upgrade Mizuho Neutral → Buy $21 → $35
Oct-24-19Initiated Oppenheimer Perform $18
Oct-08-19Downgrade Goldman Buy → Sell $54 → $16
Aug-09-19Downgrade Mizuho Buy → Neutral $79 → $21
Aug-09-19Downgrade JP Morgan Overweight → Neutral $62 → $33
Aug-09-19Downgrade Jefferies Buy → Hold $59 → $23
Mar-15-19Initiated SVB Leerink Mkt Perform $38
Dec-13-18Initiated Goldman Buy $62
Jun-11-18Downgrade H.C. Wainwright Buy → Neutral $54
Jun-04-18Reiterated H.C. Wainwright Buy $125 → $97
Apr-20-18Initiated Seaport Global Securities Buy $120
Apr-13-18Resumed Piper Jaffray Overweight $125
Mar-27-21 11:31AM  
Feb-26-21 09:09AM  
07:20AM  
03:11AM  
01:01AM  
Feb-25-21 05:10PM  
03:15PM  
Feb-18-21 05:30PM  
Feb-17-21 04:19PM  
09:25AM  
08:00AM  
07:59AM  
Feb-08-21 07:19AM  
Jan-24-21 06:08AM  
Jan-06-21 05:00PM  
07:30AM  
Jan-05-21 04:20PM  
Dec-22-20 11:03AM  
08:30AM  
Dec-18-20 08:15PM  
Dec-16-20 10:45AM  
Dec-15-20 08:30AM  
Dec-08-20 06:00AM  
Dec-07-20 04:00PM  
Dec-05-20 11:32AM  
Nov-11-20 02:00PM  
Nov-10-20 06:47AM  
Nov-09-20 09:04AM  
Nov-06-20 02:01AM  
Nov-05-20 08:00PM  
04:15PM  
04:00PM  
Nov-04-20 10:15AM  
Oct-29-20 06:00PM  
12:34PM  
Oct-28-20 06:00PM  
12:32PM  
Oct-27-20 07:30AM  
Oct-05-20 03:27PM  
Sep-28-20 05:24PM  
Sep-24-20 06:47PM  
Sep-05-20 11:32AM  
Aug-12-20 09:42AM  
08:00AM  
Aug-07-20 11:35AM  
Aug-06-20 07:00PM  
04:15PM  
Aug-05-20 11:15AM  
Jul-30-20 12:33PM  
Jul-28-20 06:00PM  
Jun-23-20 09:46PM  
Jun-14-20 09:25PM  
Jun-06-20 11:31AM  
Jun-04-20 05:00PM  
May-29-20 05:00PM  
May-26-20 11:11AM  
May-22-20 08:30AM  
May-18-20 08:05AM  
May-17-20 07:13PM  
May-12-20 06:27AM  
May-08-20 10:29AM  
03:57AM  
03:31AM  
May-07-20 05:55PM  
04:15PM  
Apr-30-20 12:33PM  
Apr-28-20 05:00PM  
Apr-09-20 06:08PM  
Apr-06-20 06:24AM  
Mar-29-20 10:51PM  
Mar-28-20 11:30AM  
Mar-11-20 09:19PM  
Mar-01-20 09:15AM  
Feb-28-20 06:30PM  
08:15AM  
04:39AM  
Feb-27-20 05:35PM  
04:15PM  
Feb-20-20 12:31PM  
Feb-18-20 05:00PM  
Feb-17-20 10:27AM  
Feb-10-20 02:56PM  
09:28AM  
Feb-06-20 05:50PM  
Feb-03-20 09:12AM  
08:00AM  
Jan-29-20 03:46PM  
Jan-27-20 09:08AM  
Jan-24-20 07:02PM  
Jan-23-20 11:43AM  
Jan-21-20 05:53PM  
Jan-16-20 01:37PM  
Jan-15-20 04:08PM  
10:27AM  
10:23AM  
09:17AM  
08:22AM  
07:30AM  
04:44AM  
Jan-14-20 10:47PM  
Nektar Therapeutics, a biopharmaceutical company, researches and develops drug candidates for cancer and auto-immune disease in the United States. The company develops Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of non-small cell lung cancer and immuno-oncology; and phase 1B clinical trial to treat COVID-19.It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat locally advanced or metastatic solid tumor malignancies, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CHESS ROBERTDirectorApr 14Option Exercise13.808,000110,400288,573Apr 16 06:02 PM
CHESS ROBERTDirectorApr 14Sale18.988,000151,840280,573Apr 16 06:02 PM
Zalevsky JonathanChief R&D OfficerFeb 16Sale22.3724,141540,034266,176Feb 18 07:07 PM
Wilson Mark AndrewSVP & General CounselFeb 16Sale22.372,17348,61076,727Feb 18 07:06 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 16Sale22.3711,705261,841164,552Feb 18 07:05 PM
NORTHCOTT JOHNSVP & Chief Commercial OfficerFeb 16Sale22.3715,358343,558213,192Feb 18 07:03 PM
ROBIN HOWARD WPresident & CEOFeb 16Sale22.3711,495257,143447,198Feb 18 07:04 PM
Labrucherie Gil MSVP, COO & CFOFeb 16Sale22.377,977178,445258,996Feb 18 07:03 PM
ROBIN HOWARD WPresident & CEOFeb 04Option Exercise8.80150,0001,320,000608,693Feb 04 08:43 PM
Labrucherie Gil MSVP, COO & CFOFeb 04Option Exercise8.8050,000440,000316,973Feb 04 08:42 PM
Labrucherie Gil MSVP, COO & CFOFeb 04Sale19.8150,000990,500266,973Feb 04 08:42 PM
ROBIN HOWARD WPresident & CEOFeb 04Sale20.29150,0003,042,906458,693Feb 04 08:43 PM
ROBIN HOWARD WPresident & CEOFeb 03Option Exercise8.80150,0001,320,000608,693Feb 04 08:43 PM
Labrucherie Gil MSVP, COO & CFOFeb 03Option Exercise8.8050,000440,000316,973Feb 04 08:42 PM
Labrucherie Gil MSVP, COO & CFOFeb 03Sale19.6150,000980,500266,973Feb 04 08:42 PM
ROBIN HOWARD WPresident & CEOFeb 03Sale19.72150,0002,958,000458,693Feb 04 08:43 PM
Wilson Mark AndrewSVP & General CounselFeb 03Sale19.455,344103,94178,900Feb 04 08:44 PM
Labrucherie Gil MSVP, COO & CFOFeb 02Option Exercise8.8050,000440,000316,973Feb 04 08:42 PM
ROBIN HOWARD WPresident & CEOFeb 02Option Exercise8.80150,0001,320,000608,693Feb 04 08:43 PM
ROBIN HOWARD WPresident & CEOFeb 02Sale19.77150,0002,966,025458,693Feb 04 08:43 PM
Labrucherie Gil MSVP, COO & CFOFeb 02Sale20.1750,0001,008,629266,973Feb 04 08:42 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerJan 28Option Exercise8.8075,000660,000251,257Jan 29 06:10 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerJan 28Sale18.6275,0001,396,500176,257Jan 29 06:10 PM
GREER R SCOTTDirectorJan 05Option Exercise13.8040,000552,000225,674Jan 05 05:09 PM
Myriam CuretDirectorDec 15Sale17.821,56027,79919,240Dec 17 06:08 PM
Zalevsky JonathanChief R&D OfficerNov 23Sale16.4016,380268,632250,317Nov 25 06:09 PM
Zalevsky JonathanChief R&D OfficerNov 16Sale16.9329,618501,433266,697Nov 18 07:08 PM
Wilson Mark AndrewSVP & General CounselNov 16Sale16.931,53926,05549,850Nov 18 07:07 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerNov 16Sale16.9311,976202,754159,757Nov 18 07:05 PM
ROBIN HOWARD WPresident & CEONov 16Sale16.9311,975202,737352,043Nov 18 07:04 PM
Labrucherie Gil MSVP, COO & CFONov 16Sale16.938,276140,113226,973Nov 18 07:03 PM
Ajer Jeffrey RobertDirectorSep 28Sale17.253,25056,06225,975Sep 30 07:03 PM
CHESS ROBERTDirectorSep 25Sale17.755,50097,625280,573Sep 25 08:16 PM
Ajer Jeffrey RobertDirectorSep 21Sale19.742,25044,41520,125Sep 21 08:58 PM
Labrucherie Gil MSVP, COO & CFOSep 17Sale19.962,00039,920235,249Sep 21 08:59 PM
CHESS ROBERTDirectorSep 08Option Exercise9.248,00073,920284,973Sep 10 08:19 PM
CHESS ROBERTDirectorSep 08Sale18.538,000148,240276,973Sep 10 08:19 PM
WHITFIELD ROY ADirectorSep 04Option Exercise9.2430,000277,200228,250Sep 08 06:18 PM
Labrucherie Gil MSVP, COO & CFOAug 18Sale19.682,00039,360237,249Aug 19 06:37 PM
Labrucherie Gil MSVP, COO & CFOAug 17Sale19.676,245122,839239,249Aug 19 06:37 PM
Zalevsky JonathanChief R&D OfficerAug 17Sale19.6726,200515,354296,315Aug 19 06:41 PM
Wilson Mark AndrewSVP & General CounselAug 17Sale19.671,52930,07551,389Aug 19 06:40 PM
ROBIN HOWARD WPresident & CEOAug 17Sale19.6711,885233,778364,018Aug 19 06:38 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerAug 17Sale19.671,36726,889171,733Aug 19 06:39 PM
GREER R SCOTTDirectorJul 09Option Exercise9.2440,000369,600191,583Jul 10 07:06 PM
GREER R SCOTTDirectorJul 09Sale25.0015,009375,225176,574Jul 10 07:06 PM
CHESS ROBERTDirectorJul 08Option Exercise9.248,00073,920284,973Jul 10 07:05 PM
CHESS ROBERTDirectorJul 08Sale24.588,000196,640276,973Jul 10 07:05 PM
Labrucherie Gil MSVP, COO & CFOMay 19Sale22.622,00045,240245,494May 20 06:29 PM
Zalevsky JonathanChief R&D OfficerMay 18Sale22.514,558102,601322,515May 20 06:33 PM
Wilson Mark AndrewSVP & General CounselMay 18Sale22.511,52934,41852,418May 20 06:32 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerMay 18Sale22.511,36730,771172,719May 20 06:31 PM
Labrucherie Gil MSVP, COO & CFOMay 18Sale22.515,727128,915247,494May 20 06:29 PM
ROBIN HOWARD WPresident & CEOMay 18Sale22.518,968201,870375,903May 20 06:30 PM